GRACE is very excited to bring you more of our program on supportive care in cancer treatment.Arjun Gupta, MD, one…
Browsing: Breast
Breast Cancer
Ramon Parsons, MD, PhD @Ramon_Parsons of @IcahnMountSinai discusses a novel agent that degrades a protein called EZH2 that drives the…
Ramon Parsons, MD, PhD @Ramon_Parsons of @IcahnMountSinai discusses a novel agent that degrades a protein called EZH2 that drives the…
Hope Rugo, MD of @UCSFMedicine discusses the SOPHIA Study. _____________ MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering…
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of…
Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19. __________ The study is…
Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19. __________ The study is…
Jennifer Crozier, MD of @BaptistHealthSA discusses the FLEX real world data in early stage breast cancer.
William Audeh, MD of @Agendia discusses new data presented at SABCS demonstrating how genomic profiling benefits early stage breast cancer.
– TAILORx Study Featured in William L. McGuire Memorial Lecture Award at 2019 San Antonio Breast Cancer Symposium® – New…
MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results for Kisqali plus fulvestrant, reducing…
First metastatic triple-negative breast cancer patient showed no detectable circulating tumor cells (CTC) or putative metastatic tumor cells (EMTs) in…
Oluwadamilola “Lola” Fayanju, MD @DrLolaFayanju of @DukeCancer answers nodal response to neoadjuvant chemotherapy predicts receipt of radiation therapy: how can…
Oluwadamilola “Lola” Fayanju, MD @DrLolaFayanju of @DukeCancer explains the nodal response to neoadjuvant chemotherapy predicts receipt of radiation therapy after…
V.K. Gadi, MD of @SeattleCCA answers commonly asked questions of the AVIATOR study and shares how it will affect future…
V.K. Gadi, MD of @SeattleCCA discusses the AVIATOR study for HER2-positive metastatic breast cancer. __________ Read here:Â https://www.seattlecca.org/clinical-trials/breast-cancer-nct03414658
Address to Japan Society of Clinical Oncology focuseson opportunities to expand benefits to more patients Accomplished surgeon-scientist joined Roswell Park…
Peter O’Donnell, MD of @UChicagoMed provides results from biomarkers in patients with locally advanced metastatic urothelial carcinoma treated with durvalumab…
Peter O’Donnell, MD of @UChicagoMed explains biomarkers in patients with locally advanced metastatic urothelial carcinoma treated with durvalumab in phase…
Carol DeSantis, MPH @caroldesantis6 of @AmericanCancer provides information on trends in breast cancer death rates.
Carol DeSantis, MPH @caroldesantis6 of @AmericanCancer explains breast cancer trends in the U.S.
Courtney Williams, MPH @cphilwil of @ONealCancerUAB explains findings in a new study that results in lower costs and how this…
Courtney Williams, MPH @cphilwil of @ONealCancerUAB explains findings in a new study that results in lower costs for patients with…
Zhibo Ma, PhD of @salkinstitute explains mapping normal breast development to try and better understand cancer. __________ Breast cancer is…
Zhibo Ma, PhD of @salkinstitute explains how this affects treatment and clinicians today. __________ Breast cancer is one of the…
Zhibo Ma, PhD of @salkinstitute answers common questions asked by colleagues regarding measuring chromatin accessibility changes in breast cancer. ________…
Breast cancer is one of the most common cancers, and some types are among the hardest to treat. The different…
Xiao-Ou Shu, MD of @VUMChealth explains how oncologists should treat male breast cancer patients and how it will affect clinicians.…
Research from the UAB’s O’Neal Comprehensive Cancer Center finds that patients treated outside the recommendations of the NCCN Guidelines had…
Xiao-Ou Shu, MD of @VUMChealth explains that in a recent study, men have a higher mortality rate than women due…
Once breast cancer spreads to bone, treatment becomes nearly impossible. Breast cancer cells can lie dormant in the bone, often…
Men may be more likely than women to die after being diagnosed with breast cancer, particularly during the first 5…
With Breast Cancer Awareness Month Approaching, Cedars-Sinai Experts Discuss New Treatment Options for Early-Stage, Low-Risk Breast Cancer Patients LOS ANGELES…
Gregory Senofsky, MD of UCLA Health explains the standard conversion rate form lumpectomy to mastectomy. ______ FINDINGS Breast cancer surgeons…
Gregory Senofsky, MD of UCLA Health addresses how reducing the need for second surgery after lumpectomy will affect clinicians today…
Gregory Senofsky, MD of UCLA Health answers a question often asked by colleagues. ______ FINDINGS Breast cancer surgeons performing lumpectomies…
Gregory Senofsky, MD of UCLA Health explains the intraoperative teamwork that greatly reduces the need for second surgery after lumpectomy.…
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains…
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center provides…
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of…
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of…
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of…
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology shares the transition from volume to value in…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology describes the factors that influence cost in novel…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology discusses the outcomes from the MONALEESA-7 trial in…
GRACEcast-133_Breast_Elderly Breast Cancer Part 4 Advanced and Functional Assessment of Patients
GRACEcast-132_Breast_Elderly Breast Cancer Part 3 Surgery and the Value of Adjuvant Therapy
GRACEcast-130_Breast_Elderly Breast Cancer Part 2 Prevention Screening and Goals of Treatment
GRACEcast-128_Breast_Older Women with Breast Cancer Part 1 Defining Population Trends by Age.mp4